Hybrid promoter and uses thereof
A hybrid promoter for recombinant expression of proteins of interest is disclosed that combines a mCMV enhancer sequence with a rat EF-1alpha intron sequence. Also disclosed are an expression cassette containing the hybrid promoter and a recombinant expression vector containing the expression cassette. A mammalian host cell, which comprises the recombinant expression vector is also disclosed, as is a method of producing a protein of interest that employs the mammalian host cell, optionally involving tetracycline-inducible expression of the protein.
1. A hybrid promoter, comprising:
(i) a murine cytomegalovirus (mCMV) enhancer sequence, comprising a mCMV enhancer element (mCMV-E) and a CMV promoter (CMV-P) sequence at its 3′ end, operably linked 5′ to a rat EF-1alpha intron sequence;
(ii) an intervening first leader sequence operably linked, 3′ to the CMV promoter sequence of the mCMV enhancer sequence, and 5′ to the rat EF-1alpha intron sequence; and
(iii) a second leader sequence operably linked 3′ to the rat EF-1alpha intron sequence.
2. The hybrid promoter of claim 1 , wherein the CMV promoter sequence at the 3′ end of the mCMV enhancer sequence comprises a segment having the nucleotide sequence of SEQ ID NO:24 or SEQ ID NO:26.
3. The hybrid promoter of claim 1 , wherein the rat EF-1alpha intron sequence comprises the nucleotide sequence of SEQ ID NO:4.
4. The hybrid promoter of claim 1 , wherein the mCMV enhancer sequence comprises the nucleotide sequence of SEQ ID NO:2 or SEQ ID NO:33; and the rat EF-1alpha intron sequence comprises the nucleotide sequence of SEQ ID NO:4.
5. The hybrid promoter of claim 4 , wherein the mCMV enhancer sequence comprises the nucleotide sequence of SEQ ID NO:2.
6. The hybrid promoter of claim 1 , wherein the first leader sequence comprises the nucleotide sequence of SEQ ID NO:3.
7. The hybrid promoter of claim 1 , wherein the second leader sequence comprises the nucleotide sequence of SEQ ID NO:5.
8. The hybrid promoter of claim 1 , further comprising one or more TetO sequences inserted within the CMV promoter sequence.
9. The hybrid promoter of claim 1 , comprising a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:30, SEQ ID NO:31, or SEQ ID NO:32.
10. The hybrid promoter of claim 1 , comprising the nucleotide sequence of SEQ ID NO:1.
11. The hybrid promoter of claim 1 , comprising the nucleotide sequence of SEQ ID NO:30.
12. The hybrid promoter of claim 1 , comprising the nucleotide sequence of SEQ ID NO:31.
13. The hybrid promoter of claim 1 , comprising the nucleotide sequence of SEQ ID NO:32.
14. An expression cassette, comprising:
(a) the hybrid promoter of claim 1 or claim 8 , operably linked 5′ to an open reading frame encoding an exogenous protein of interest; and
(b) a polyadenylation site operably linked 3′ to the open reading frame.
15. A recombinant expression vector comprising the expression cassette of claim 14 .
16. A mammalian host cell comprising the recombinant expression vector of claim 15 .
17. The mammalian host cell of claim 16 , further being capable of expressing TetR.
18. The mammalian host cell of claim 16 , being derived from a Chinese Hamster Ovary (CHO) cell.
19. The mammalian host cell of claim 18 , selected from the group consisting of a CHO-K1 cell, a DXB11 cell, and a DG44 cell.
20. A method of producing a protein of interest, comprising:
(a) culturing the mammalian host cell of claim 16 , in an aqueous medium under physiological conditions permitting expression of the protein of interest; and
(b) recovering the protein of interest from the medium.
21. A method of producing a protein of interest, comprising:
(a) culturing a mammalian host cell that comprises an expression vector comprising the hybrid promoter of claim 8 , in an aqueous medium under physiological conditions, wherein the mammalian host cell is capable of expressing TetR, whereby, in the absence of tetracycline in the medium, the expression of the protein of interest is repressed;
(b) adding tetracycline to the aqueous medium in an amount sufficient to bind TetR in the host cell, whereby expression of the protein of interest by the host cell is derepressed; and
(c) recovering the protein of interest from the medium.
22. The method of producing a protein of interest of claim 20 , wherein the aqueous medium is serum-free.
23. The method of producing a protein of interest of claim 20 , wherein culturing the mammalian host cell is in a suspension in liquid aqueous medium.
24. The method of producing a protein of interest of claim 20 , wherein culturing the mammalian host cell is in an adhesion layer on a solid or semisolid substrate.
25. The mammalian host cell of claim 17 , being derived from a Chinese Hamster Ovary (CHO) cell.
26. The mammalian host cell of claim 25 , selected from the group consisting of a CHO-K1 cell, a DXB11 cell, and a DG44 cell.
27. The method of producing a protein of interest of claim 21 , wherein the aqueous medium is serum-free.
28. The method of producing a protein of interest of claim 21 , wherein culturing the mammalian host cell is in a suspension in liquid aqueous medium.
29. The method of producing a protein of interest of claim 21 , wherein culturing the mammalian host cell is in an adhesion layer on a solid or semisolid substrate.